Investors with the goal of beating the broader market often turn to stock selection. Strategic choices in individual stocks can have a profound impact on your wealth.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
In the latest session, Relay Therapeutics Inc (NASDAQ: RLAY) closed at $6.02 down -2.75% from its previous closing price of $6.19. In other words, the price has decreased by -$2.75 from its previous closing price. On the day, 0.86 million shares were traded. RLAY stock price reached its highest trading level at $6.3797 during the session, while it also had its lowest trading level at $6.0035.
Ratios:
For a deeper understanding of Relay Therapeutics Inc’s stock, let’s take a closer look at its various ratios. For the most recent quarter (mrq), Quick Ratio is recorded 15.64 and its Current Ratio is at 15.64. In the meantime, Its Debt-to-Equity ratio is 0.07 whereas as Long-Term Debt/Eq ratio is at 0.07.
Upgrades & Downgrades
In addition, analysts’ ratings and any changes thereto give investors an idea of the stock’s future direction. In the most recent recommendation for the company, Jefferies on September 10, 2024, Upgraded its rating to Buy and sets its target price to $16 from $10.60 previously.
Insider Transactions:
Additionally, insider trades can be beneficial to investors who want to learn what the management thinks about stock prices in the future. A recent insider transaction in this stock occurred on Sep 27 ’24 when Rahmer Peter sold 245 shares for $7.51 per share. The transaction valued at 1,840 led to the insider holds 391,684 shares of the business.
Catinazzo Thomas sold 6,457 shares of RLAY for $48,184 on Sep 27 ’24. The Chief Financial Officer now owns 313,193 shares after completing the transaction at $7.46 per share. On Sep 27 ’24, another insider, Bergstrom Donald A, who serves as the President, R&D of the company, sold 648 shares for $7.51 each. As a result, the insider received 4,866 and left with 523,433 shares of the company.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, RLAY now has a Market Capitalization of 1023508352 and an Enterprise Value of 168700592. For the stock, the TTM Price-to-Sale (P/S) ratio is 27.78 while its Price-to-Book (P/B) ratio in mrq is 1.18. Its current Enterprise Value per Revenue stands at 4.792 whereas that against EBITDA is -0.459.
Stock Price History:
Over the past 52 weeks, RLAY has reached a high of $12.14, while it has fallen to a 52-week low of $5.70. The 50-Day Moving Average of the stock is -14.09%, while the 200-Day Moving Average is calculated to be -22.09%.
Shares Statistics:
For the past three months, RLAY has traded an average of 1.91M shares per day and 1121710 over the past ten days. A total of 127.46M shares are outstanding, with a floating share count of 120.66M. Insiders hold about 25.73% of the company’s shares, while institutions hold 55.85% stake in the company. Shares short for RLAY as of 1728950400 were 11855809 with a Short Ratio of 6.20, compared to 1726185600 on 9924227. Therefore, it implies a Short% of Shares Outstanding of 11855809 and a Short% of Float of 8.9099996.
